Liver disorders gene therapy - Castle Creek Pharmaceuticals
Latest Information Update: 21 Feb 2022
At a glance
- Originator Castle Creek Pharmaceuticals
- Class Fibroblast cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Liver disorders; Metabolic disorders
Most Recent Events
- 25 Jan 2022 Early research in Liver disorders in USA (Parenteral) (Castle Creek Pharmaceuticals pipeline, January 2022)
- 25 Jan 2022 Early research in Metabolic disorders in USA (Parenteral) (Castle Creek Pharmaceuticals pipeline, January 2022)